Medical disclaimer

10-year radiotherapy results for MRI-defined prostate cancer risk groups at Quironsalud Madrid

In this study of 140 consecutive patients with localized prostate cancer, 10-year survival without biochemical relapse was 86.7% in the low-risk group, 80.5% in the intermediate-risk group and 72.8% in the high-risk group, with risk groups set by multiparametric MRI (mpMRI). The patients were treated at Hospital Universitario Quirónsalud Madrid y Hospital La Luz, which is the same hospital as Quironsalud Madrid listed on Bookimed under another name.

8 min read

Prepared by Bookimed editorial team

Medical content and care coordination

Quironsalud Madrid
← All research summaries
Published research, not an individual patient story.

The source identifies treatment at the named clinic. Study results describe this cohort, not a predicted individual outcome.

Key takeaways

  • The study followed 140 consecutive patients with localized prostate adenocarcinoma for a median of 104 months after radiotherapy, with or without androgen deprivation therapy (ADT).
  • Ten-year biochemical relapse-free survival was 86.7% in the low-risk group (15 patients), 80.5% in the intermediate-risk group (80 patients) and 72.8% in the high-risk group (45 patients).
  • mpMRI changed the risk group of 36 patients (25.7%) and the TNM stage of 125 patients (89.28%).
  • No acute grade 3 toxicity occurred, and late grade 3 genitourinary and gastrointestinal toxicity were 2.8% and 0.7%.
  • These are group results from one hospital and do not predict the outcome for any individual patient.

The question this study addresses

This retrospective study from the radiation oncology team reviewed 140 consecutive patients with localized prostate adenocarcinoma. Risk groups (low, intermediate, high) were set by mpMRI findings instead of the digital rectal exam. The patients were treated at Hospital Universitario Quirónsalud Madrid y Hospital La Luz, the same hospital as Quironsalud Madrid. The authors report 10-year biochemical relapse-free, locoregional relapse-free, metastasis-free and overall survival for each group. They conclude that mpMRI is a key tool for setting risk groups and optimizing treatment.

The situation
Adults with localized prostate adenocarcinoma, grouped as low, intermediate or high risk according to mpMRI.
The treatment
Radiotherapy, with or without androgen deprivation therapy (ADT, hormone-lowering treatment).

What this evidence cannot establish

  • The study is retrospective and comes from a single center, so results may not apply to other hospitals or patients.
  • The low-risk group has only 15 patients, so its figures are less certain than the others.
  • The abstract does not give toxicity or ADT use for each risk group, and it describes patients treated at this hospital, so it says nothing about how any individual patient would do there.

Patient groups in the published study

15 patients · Published study group

Low-risk prostate cancer by MRI

Indication
Localized prostate adenocarcinoma, low risk by mpMRI
Treatment
Radiotherapy with or without ADT

15 patients

Patients whose mpMRI results placed them in the low-risk group.

Radiotherapy, with or without ADT. The abstract does not say how many received ADT.

  • 10-year biochemical relapse-free survival

    86.7%

    15 patients · Study group

    10 years

  • 10-year locoregional relapse-free survival

    86.7%

    15 patients · Study group

    10 years

  • 10-year metastasis-free survival

    93.3%

    15 patients · Study group

    10 years

  • 10-year overall survival

    100%

    15 patients · Study group

    10 years

Reported risks

  • Study-wide: no acute grade 3 toxicity occurred, and late grade 3 sexual toxicity was 1.2% across all 140 patients. Toxicity per risk group is not stated.

Limits of this evidence

  • This is the smallest group, with 15 patients.
  • Per-group toxicity and ADT use are not stated.

For a clinic assessment

  • Prostate MRI report and images
  • Biopsy pathology report and PSA test results

80 patients · Published study group

Intermediate-risk prostate cancer by MRI

Indication
Localized prostate adenocarcinoma, intermediate risk by mpMRI
Treatment
Radiotherapy with or without ADT

80 patients

Patients whose mpMRI results placed them in the intermediate-risk group, the largest group in the study.

Radiotherapy, with or without ADT. The abstract does not say how many received ADT.

  • 10-year biochemical relapse-free survival

    80.5%

    80 patients · Study group

    10 years

  • 10-year locoregional relapse-free survival

    86.1%

    80 patients · Study group

    10 years

  • 10-year metastasis-free survival

    92.6%

    80 patients · Study group

    10 years

  • 10-year overall survival

    76%

    80 patients · Study group

    10 years

Reported risks

  • Study-wide: no acute grade 3 toxicity occurred, and late grade 3 genitourinary toxicity was 2.8% across all 140 patients. Toxicity per risk group is not stated.

Limits of this evidence

  • Per-group toxicity and ADT use are not stated.
  • Patients who moved from intermediate to high risk because of mpMRI had a trend toward more metastatic relapse (20% vs. 1.81%, p = 0.059), which is not a firm difference.

For a clinic assessment

  • Prostate MRI report and images
  • Biopsy pathology report, PSA history and any ADT records

45 patients · Published study group

High-risk prostate cancer by MRI

Indication
Localized prostate adenocarcinoma, high risk by mpMRI
Treatment
Radiotherapy with or without ADT

45 patients

Patients whose mpMRI results placed them in the high-risk group. Two deaths from prostate cancer were reported in this group.

Radiotherapy, with or without ADT. The abstract does not say how many received ADT.

  • 10-year biochemical relapse-free survival

    72.8%

    45 patients · Study group

    10 years

  • 10-year locoregional relapse-free survival

    78.7%

    45 patients · Study group

    10 years

  • 10-year metastasis-free survival

    82.1%

    45 patients · Study group

    10 years

  • 10-year overall survival

    77%

    45 patients · Study group

    10 years

  • Deaths from prostate cancer

    2 / 45

    45 patients · Study group

    not stated

Reported risks

  • Study-wide: late grade 3 gastrointestinal toxicity was 0.7% across all 140 patients. Toxicity per risk group is not stated.

Limits of this evidence

  • Per-group toxicity and ADT use are not stated.
  • The time point of the two prostate cancer deaths is not stated.

For a clinic assessment

  • Prostate MRI report and images with TNM staging
  • Biopsy pathology report, PSA history and any ADT records

Results and limits of the study

At 10 years, biochemical relapse-free survival was 86.7% (low risk), 80.5% (intermediate) and 72.8% (high). Locoregional relapse-free survival was 86.7%, 86.1% and 78.7%. Metastasis-free survival was 93.3%, 92.6% and 82.1%. Overall survival was 100%, 76% and 77%. Locoregional relapse was strongly associated with distant relapse (OR = 9.28; 95% CI 2.60-33.31).

  • Patients who changed risk group after mpMRI

    36 / 14025.7%

    140 patients · Whole cohort

    not stated

  • Patients who changed TNM stage after mpMRI

    125 / 14089.28%

    140 patients · Whole cohort

    not stated

  • Late grade 3 genitourinary toxicity

    2.8%

    140 patients · Whole cohort

    not stated

  • Late grade 3 gastrointestinal toxicity

    0.7%

    140 patients · Whole cohort

    not stated

Risks reported by the source

  • No acute grade 3 toxicity occurred.
  • Late grade 3 genitourinary toxicity was 2.8%, late grade 3 gastrointestinal toxicity was 0.7%, and late grade 3 sexual toxicity was 1.2%.

Limitations and unknowns

  • How many patients in each group received ADT, and for how long.
  • Toxicity by risk group, since the abstract reports it only for all patients together.
  • The exact radiotherapy technique and dose.
  • How these group results would apply to an individual patient.

What to clarify in your treatment plan

Before booking, ask the clinic whether the treating team can review your own mpMRI, biopsy and PSA results. Also ask which radiotherapy approach and whether ADT would be discussed for your situation, and how follow-up visits are organized. Ask what to expect in terms of side effects and who to contact if symptoms appear.

Quironsalud Madrid: clinic profile

  • The patients in this study were treated at Hospital Universitario Quirónsalud Madrid y Hospital La Luz, which is the same hospital as Quironsalud Madrid in Madrid, Spain.
  • The Quironsalud Madrid profile and its radiotherapy for prostate cancer service are listed on Bookimed.
Quironsalud Madrid

Quironsalud Madrid

Madrid, Spain

3.8/5 · 6 Bookimed reviews (current clinic profile)

Safety and recovery: general information

General patient guidance, provided separately from the case evidence. Follow your treating team's instructions.

Possible side effects

  • Some patients may have problems getting or maintaining erections after external radiation therapy, and these usually develop slowly over time.

    Ask the team how sexual function is monitored after treatment.

  • Radiation therapy can cause fatigue that may last until a few weeks or months after treatment stops.

    Ask how to plan work and daily activity during treatment.

  • If the lymph nodes around the prostate are damaged by radiation, fluid can collect in the legs or genital region over time, causing swelling and pain.

    Ask whether lymph node areas would be treated in your plan.

Recovery and aftercare

  • For most types of external radiation, treatments are given 5 days a week in an outpatient center, for at least several weeks.

    Ask about the planned schedule and travel or stay arrangements.

  • Symptoms are often worse in the first few months after treatment and tend to improve over time.

    Ask what follow-up is offered in the first months.

  • Many side effects can be treated or prevented, and most will go away after treatment stops.

    Ask which supportive treatments the clinic offers.

Suitability and cautions

  • The American Cancer Society says brachytherapy alone is generally used only in men with early-stage prostate cancer in a lower-risk group.

    Ask whether this applies to your risk group.

  • For men who had a transurethral resection of the prostate (TURP) or who already have urinary problems, the risk of urinary side effects may be higher, and brachytherapy might not work as well with large prostate glands.

    Tell the clinic about prior prostate surgery, urinary symptoms and prostate size.

When to contact the clinic

  • You may need to urinate more often, have a burning sensation when you urinate, or find blood in your urine.

    Contact your treating team and describe the symptoms.

  • Swelling and pain in the legs or genital region can appear if the lymph nodes around the prostate are damaged by radiation.

    Contact your treating team promptly if this appears.

Request a personal plan from the clinic

Ask Quironsalud Madrid for a review of your MRI and radiotherapy options for prostate cancer

Bookimed shares your MRI, biopsy and PSA records with the clinic coordinator. The clinic then tells you whether and how its team can assess your case.

Ask the clinic for a current, itemized quotation. Published evidence does not establish package inclusions or a current price.

Frequently asked questions

Who ran this study and where were the patients treated?

The study was run by the radiation oncology team at Hospital Universitario Quirónsalud Madrid y Hospital La Luz, and the patients were treated there. That hospital is the same one listed on Bookimed as Quironsalud Madrid. Bookimed did not run or fund the study. It is a retrospective series of 140 consecutive patients, and this page summarizes the published abstract only.

Did radiotherapy work for low-, intermediate- and high-risk groups?

Results were reported for each group, and they were lower as risk rose. Ten-year biochemical relapse-free survival was 86.7% in the low-risk group, 80.5% in the intermediate-risk group and 72.8% in the high-risk group. These are group figures from one hospital and do not predict the result for any individual patient.

How common were serious side effects in the study?

No acute grade 3 toxicity occurred. Late grade 3 genitourinary toxicity was 2.8%, late grade 3 gastrointestinal toxicity was 0.7%, and late grade 3 sexual toxicity was 1.2%. The abstract does not break toxicity down by risk group, and it does not describe milder side effects.

What did mpMRI change in this study?

mpMRI changed the risk group of 36 patients (25.7%) and the TNM stage of 125 patients (89.28%) compared with the usual digital rectal exam. Patients who moved from intermediate to high risk had a trend toward more metastatic relapse (20% vs. 1.81%, p = 0.059). The authors conclude that mpMRI is a key tool for setting risk groups.

Sources and scope

This page was prepared from the published abstract of the study, using only the numbers and statements it contains. Side-effect and recovery information comes from cited American Cancer Society and NHS sources.

  1. 1. Duque-Santana et al. – Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer.

    Retrospective single-center consecutive series · 2023

    140 adults with localized prostate adenocarcinoma, grouped as low, intermediate or high risk by mpMRI

    Follow-up: Median follow-up of 104 months

    The page relies on the abstract alone, which gives no radiotherapy details, no per-group toxicity and no per-group ADT use.

  2. 2. American Cancer Society
  3. 3. NHS
  4. 4. Quironsalud Madrid on Bookimed

Scope and limitations

  • A research summary is not an individual medical recommendation.
  • Group results describe the study participants, not a forecast for any one patient.

Related procedures

About the editorial team

Bookimed editorial team

Prepared by

Bookimed editorial team

Medical content and care coordination

Bookimed prepares evidence summaries from published medical sources and anonymized care records. The clinic and any doctors named on this page are identified separately in their own sections.

About this page

This page summarizes cited evidence and links to current Bookimed provider profiles. It does not replace an individual diagnosis or treatment plan. Published group results are not a guarantee of your outcome.

Clinic profiles and package availability come from the current Site catalog. Historical costs and research measurements keep their original context.

Report a correction